Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Assets: 2012-2025

Historic Assets for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $1.4 billion.

  • Agios Pharmaceuticals' Assets fell 22.66% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 22.66%. This contributed to the annual value of $1.7 billion for FY2024, which is 77.48% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Assets stood at $1.4 billion, which was down 5.81% from $1.5 billion recorded in Q2 2025.
  • Agios Pharmaceuticals' Assets' 5-year high stood at $2.5 billion during Q1 2021, with a 5-year trough of $773.1 million in Q2 2024.
  • In the last 3 years, Agios Pharmaceuticals' Assets had a median value of $1.2 billion in 2023 and averaged $1.2 billion.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Assets soared by 211.16% in 2021, and later crashed by 46.32% in 2022.
  • Agios Pharmaceuticals' Assets (Quarterly) stood at $1.4 billion in 2021, then declined by 13.84% to $1.2 billion in 2022, then fell by 24.35% to $937.1 million in 2023, then soared by 77.48% to $1.7 billion in 2024, then fell by 22.66% to $1.4 billion in 2025.
  • Its Assets was $1.4 billion in Q3 2025, compared to $1.5 billion in Q2 2025 and $1.6 billion in Q1 2025.